Amgen比2025年第2季度收入估计数高,提高了全年利润预测。 Amgen beat earnings estimates in Q2 2025 and raised its full-year profit forecast.

Amgen Inc.报告2025年第二季度收入强劲,据EPS估计超过6.02美元,收入为7.4美元,收入为9.18亿美元,比上一年增加9.4%。 Amgen Inc. reported strong second-quarter 2025 earnings, posting $6.02 EPS—surpassing estimates by $0.74—and $9.18 billion in revenue, a 9.4% year-over-year increase. 该公司将其2025年全年EPS指南提高到20.20-21.30美元,分析师预测为20.62美元。 The company raised its 2025 full-year EPS guidance to $20.20–$21.30, with analysts forecasting $20.62. 机构投资者拥有76.5%的股票,而内部投资者持有0.76%的股份。 Institutional investors own 76.5% of shares, while insiders hold 0.76%. 股票交易额接近291.16美元,市场上限为156.75亿美元,股息收益率为3.3%, " 股价 " 一致评分为300.94美元,平均价格目标是300.94美元。 The stock, trading near $291.16 with a $156.75 billion market cap, has a 3.3% dividend yield and a consensus "hold" rating with a $300.94 average price target. Amgen的产品组合包括骨质疏松症、癌症、自发免疫疾病和稀有疾病的关键疗法。 Amgen’s product portfolio includes key therapies for osteoporosis, cancer, autoimmune diseases, and rare disorders.